<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overexpression of the transcriptional regulator Myc is thought to be the cause or a contributing factor in the development of a large number of human <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and certain other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> constitutes a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressive mechanism, particularly in the context of Myc overexpression </plain></SENT>
<SENT sid="2" pm="."><plain>Accordingly, <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development in Eμ-Myc transgenic mice, which mimic the Myc/IgH chromosomal translocation that causes Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, is accelerated by concomitant overexpression of anti-apoptotic Bcl-2 family members or loss of pro-apoptotic <z:chebi fb="0" ids="30153">BH3</z:chebi>-only proteins, such as <z:chebi fb="3" ids="33173">Bim</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="3" ids="33173">Bim</z:chebi> binds with high affinity to <z:hpo ids='HP_0000001'>all</z:hpo> pro-survival Bcl-2-like proteins and can also interact with Bax/Bak, but it remains unclear which of these interactions are critical for its <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressive function </plain></SENT>
<SENT sid="4" pm="."><plain>We have previously generated knock-in mutant mice in which the <z:chebi fb="0" ids="30153">BH3</z:chebi> region of <z:chebi fb="3" ids="33173">Bim</z:chebi> has been exchanged with that for Bad, Noxa or Puma so that it can only bind to select pro-survival Bcl-2-like proteins: <z:chebi fb="3" ids="33173">Bim</z:chebi>(Bad) binding to Bcl-2, Bcl-x(L) and Bcl-w, but not Mcl-1 or A1; <z:chebi fb="3" ids="33173">Bim</z:chebi>(Noxa) binding only to Mcl-1 and A1 and as a control, <z:chebi fb="3" ids="33173">Bim</z:chebi>(Puma), which can still bind <z:hpo ids='HP_0000001'>all</z:hpo> pro-survival Bcl-2-like proteins </plain></SENT>
<SENT sid="5" pm="."><plain>We have now inter-crossed these <z:chebi fb="3" ids="33173">Bim</z:chebi> mutant mice with Eμ-Myc transgenic mice, and found that both the <z:chebi fb="3" ids="33173">Bim</z:chebi>(Bad) and the <z:chebi fb="3" ids="33173">Bim</z:chebi>(Noxa) mutations but not the <z:chebi fb="3" ids="33173">Bim</z:chebi>(Puma) mutation greatly accelerate Myc-induced <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development and increase leukemic burden </plain></SENT>
<SENT sid="6" pm="."><plain>These results demonstrate that for optimal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressive activity, <z:chebi fb="3" ids="33173">Bim</z:chebi> must be able to interact with <z:hpo ids='HP_0000001'>all</z:hpo> and not just select pro-survival Bcl-2 family members </plain></SENT>
</text></document>